PKD Awareness Day: Video Challenge
Are you ready to take on the challenge? Help spread the word about PKD Awareness Day and what it's like to live with polycystic kidney disease! Record a short video with your smartphone and tell us your story...
10 Simple Things You Can Do to Support Your Favourite Nonprofit
Check out these 10 simple ways you can support your favourite nonprofits. They take less than five minutes and come at no cost!
2018 Bike to the Moon Campaign Wrap Up
In 2016, an Ontario family impacted by PKD for generations got together with their friends to bike the Bruce Trail in an effort to raise money for PKD research. They travelled 480 km and raised over $11,000. This year, Bike to the Moon participants across Canada travelled over 4,000 km......
PKD Awareness Day: Local Proclamations
Each year, Health Canada recognizes September 4th as National PKD Awareness Day! This year we are looking for volunteers who want to help spread awareness in their own communities by working with us to secure local proclamations.
Register Today for the 2018 Walk to END PKD
Join us for the 2018 Walk to END PKD, the PKD Foundation of Canada's signature fundraising campaign!
2017 Canadian PKD Symposium is Now Online
On November 25, 2017 we held our biennial Canadian PKD Symposium, which included participants from the PKD medical community and various renal healthcare centres, as well as PKD patients, their families and loved ones.
PKD Foundation of Canada Awarded the Upper Canada Medal
On Monday, April 9, the PKD Foundation of Canada attended the Can-SOLVE CKD SPOR Initiative reception where we were awarded the Pewter Upper Canada Medal by the Toronto General & Western Hospital Foundation for our support of Dr. York Pei’s Hereditary Kidney Disease Clinic at Toronto General Hospital. We wish...
The FDA Approves JYNARQUE™ as the First Treatment in the United States for Adult Patients with ADPKD
We’re excited to announce that on Tuesday, April 24, 2018, the U.S. Food and Drug Administration (FDA) granted approval of JYNARQUE™ (pronounced jin-AR-kew and also known as tolvaptan) to be the first treatment in the United States for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common...